A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression (NCT07023627)

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

1. Histological diagnosis of a high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer.
2. Have platinum-resistant disease:
3. Participants who have only had 1 line of platinum-based therapy must have received at least 4 cycles of a platinum-containing regimen.
4. Participants who have received 2 to 4 lines of platinum-based therapy must have progressed on or within 6 months after the last dose of platinum.
5. Willingness to undergo a pretreatment biopsy. Note: Tissue from a fresh pretreatment biopsy is preferred, however an archival sample is acceptable as long as the sample is no older than 5 years.
6. Received at least 1 and no more than 4 prior lines of systemic therapy following the initial diagnosis, after which single-agent therapy is considered an appropriate next therapeutic option.
7. Must have received bevacizumab unless there was a contraindication for its use.
8. If the tumor tests positive for FRα, participants must have received mirvetuximab soravtansine unless there is an exception for its use on medical grounds.

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (74 Sites)

• Usa Health Mitchell Cancer Institute — Mobile, Alabama
• University of California, Los Angeles Medical Center — Los Angeles, California
• Scripps Healthscripps Mercy Hospital Prebys Cancer Center — San Diego, California
• Medstar Georgetown University Hospital — Washington D.C., District of Columbia
• Florida Cancer Specialists & Research Institute — Fort Myers, Florida
• Sylvester Comprehensive Cancer Center — Miami, Florida
• Mount Sinai Comprehensive Cancer Center — Miami Beach, Florida
• Florida Cancer Specialists & Research Institute — West Palm Beach, Florida
• Northeast Georgia Medical Center Gainesville — Gainesville, Georgia
• Parkview Research Center — Fort Wayne, Indiana
• University of Iowa Hospital and Clinics — Iowa City, Iowa
• Norton Cancer Institute — Louisville, Kentucky
• Trials365, Llc — Shreveport, Louisiana
• Greater Baltimore Medical Center — Baltimore, Maryland
• Massachusetts General Hospital — Boston, Massachusetts
• Umass Memorial Medical Center, Inc. — Worcester, Massachusetts
• University of Michigan Health System — Ann Arbor, Michigan
• Minnesota Oncology-Minneapolis — Minneapolis, Minnesota
• University of Mississippi Medical Center — Jackson, Mississippi
• Washington University — St Louis, Missouri
• St. Vincent Regional Hospital - West End Clinic — Billings, Montana
• Nebraska Methodist Hospital — Omaha, Nebraska
• John Theurer Cancer Center, Hackensack University Medical Center — Hackensack, New Jersey
• Laura and Isaac Perlmutter Cancer Center — New York, New York
• State University of New York Upstate Medical Unive — Syracuse, New York

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.